Informations générales (source: ClinicalTrials.gov)

NCT03470467 En recrutement IDF
Posterior Reversible Encephalopathy Syndrome in the Critically Ill Patients
Observational [Patient Registry]
  • Encéphalopathies
  • Syndrome
  • Leucoencéphalopathie postérieure
Ictal Group (Voir sur ClinicalTrials)
mars 2018
décembre 2028
09 mai 2026
Posterior Reversible Encephalopathy Syndrome prospective (PRES) registry. Data collection using a standardized form : demographic data and data related to the PRES, including circumstances of onset, dates and times of onset and of symptoms control, on-scene clinical findings, clinical and radiological features of PRES, pre-hospital and hospital care providers, timing of antiepileptic, antihypertensive drugs and supportive treatments, results of etiological investigations, cause of PRES, type and dosage of antiepileptic and antihypertensive drugs. Dates and times of EEG monitoring, EEG results, radiological and biological investigations. Outcomes including vital status and Glasgow Outcome Scale score at ICU and hospital discharge, day-90 and 1-year after SE and determined based on data in the ICU and/or neurologist charts and/or patients phone interview
 Voir le détail

Etablissements

Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
CH DE VERSAILLES SITE ANDRE MIGNOT Stephane LEGRIEL, MD En recrutement IDF Contact (sur clinicalTrials)

Critères

Tous


- age >= 18 years

- Posterior Reversible Encephalopathy Syndrome defined as:

- combination of consciousness impairment, seizure activity, headaches, visual
abnormalities, nausea/vomiting, and focal neurological signs AND

- cerebral imaging abnormalities involving the white matter (brain CT scan
hypodensities AND/OR Brain MRI hypoT1, hyper T2 FLAIR)

- intensive care unit admission

Exclusion Criteria:


- normal cerebral imaging